tbuckley/cabot-search huggingface dataset:
Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Glycemia and Childhood Glucose Metabolism
Authors: Denise M. Scholtens, Alan Kuang, Lynn P. Lowe, Jill Hamilton, Jean M. Lawrence, Yael Lebenthal, Wendy J. Brickman, Peter Clayton, Ronald C. Ma, David McCance, Wing Hung Tam, Patrick M. Catalano, Barbara Linder, Alan R. Dyer, William L. Lowe, Boyd E. Metzger, Chaicharn Deerochanawong, Thadchanan Tanaphonpoonsuk, Sukeeta Binratkaew Uraiwan Chotigeat, Wanee Manyam, Martinette Forde, Andre Greenidge, Kathleen Neblett, Paula Michele Lashley, Desiree Walcott, Katie Corry, Loraine Francis, Jo-anne Irwin, Anne Langan, David R. McCance, Maureen Mousavi, Ian Young, Jennifer Gutierrez, Jennifer Jimenez, Jean M. Lawrence, David A. Sacks, Harpreet S. Takhar, Elizabeth Tanton, Wendy J. Brickman, Jennifer Howard, Jami L. Josefson, Lauren Miller, Jacqui Bjaloncik, Patrick M. Catalano, Ajuah Davis, Michaela Koontz, Larraine Presley, Shoi Smith, Amanda Tyhulski, Albert Martin Li, Ronald C. Ma, Risa Ozaki, Wing Hung Tam, Michelle Wong, Cindy Siu Man Yuen, Peter E. Clayton, Aysha Khan, Avni Vyas, Michael Maresh, Hadasse Benzaquen, Naama Glickman, Alona Hamou, Orna Hermon, Orit Horesh, Yael Keren, Yael Lebenthal, Shlomit Shalitin, Kristina Cordeiro, Jill Hamilton, Hahn Y. Nguyen, Shawna Steele, Fei Chen, Alan R. Dyer, Wenyu Huang, Alan Kuang, Maria Jimenez, Lynn P. Lowe, William L. Lowe, Boyd E. Metzger, Michael Nodzenski, Anna Reisetter, Denise Scholtens, Octavious Talbot, Paul Yim, David Dunger, Alicia Thomas, Mary Horlick, Barbara Linder, Aynur Unalp-Arida, Gilman Grave
Journal: Diabetes Care (2019)

This study examined associations of maternal glycemia during pregnancy with childhood glucose outcomes in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) cohort.
Prognostic impact of oral squamous cell carcinoma on 513 patients with pathologically positive lymph node metastasis: A retrospective multicenter study of the Japan Oral Oncology Group.
Authors: Souichi Yanamoto, Tadaaki Kirita, Nobuhiro Yamakawa, Michihiro Ueda, Tetsuro Yamashita, Yoshihide Ota, Mitsunobu Otsuru, Hiroshi Kurita, Takahiro Kamata, Masaya Okura, Tomonao Aikawa, Takahide Komori, Takashi Shigeta, Satoshi Yokoo, Masaru Ogawa, Masahiro Umeda
Journal: Journal of Clinical Oncology (2014)

e17005 Background: Extracapsular spread (ECS) of pathologically positive regional lymph node metastasis (pN+) and the presence of positive margins are recognized as major adverse prognostic factors for survival in head and neck squamous cell carcinoma (HNSCC). Patients with these prognostic factors are considered at high risk for recurrence, and postoperative concurrent chemoradiotherapy (CCRT) is a widely accepted standard of care for fit patients with these high-risk features in surgical pathology. However, the specific high-risk factors for oral squamous cell carcinoma (OSCC) are still unclear. The purpose of this retrospective multicenter study was to assess the prognostic impact of OSCC on patients with pN+ and to identify high-risk patients who need postoperative radiotherapy (RT) or CCRT. Methods: We examined the records of 513 pN+ patients with OSCC who underwent neck dissection (ND). The 5-year disease specific survival (DSS) and overall survival (OS) rates served as the main outcome measures. The optimal cutoff line for number of pN+ yielding the highest statistical significance in terms of 5-year DSS and OS rates was investigated. Results: The 5-year survival rates for the 513 pN+ patients were as follows: DSS, 59.0%; and OS, 52.8%. Multivariable analysis showed that variables independently prognostic for DSS were T-stage (hazard ratio [HR] = 1.80; P < 0.001), ECS (HR = 2.27; P < 0.001), and ipsilateral lower neck metastasis (level IV/V) (HR = 1.89; P = 0.001). We identified the following three risk groups based on the number of pN+ and the presence of ECS: group 1, number of pN+ 1 and ECS-; group 2, number of pN+ 2-5 and ECS-; and group 3, number of pN+ 6≤ and/or ECS+. Postoperative adjuvant RT/CCRT improved outcomes only in group 3. Conclusions: Patients with pN+ 6≤ and/or ECS+ were found to be a “super-high-risk” group and required postoperative adjuvant RT/CCRT. To further improve the survival of advanced OSCC patients, novel approaches, such as postoperative adjuvant CCRT with molecular targeted therapy, will be required.
Variation in antibiotic use in pediatric acute lymphoblastic leukemia (ALL) by hospital pediatric volume.
Authors: Jennifer J Wilkes, Rui Xiao, Alix Eden Seif, Yuan-Shung Huang, Neika D Vendetti, Susan R. Rheingold, Richard Aplenc, Sean Hennessy, Brian Fisher
Journal: Journal of Clinical Oncology (2014)

e17703 Background: Antibiotic use in pediatric ALL patients varies significantly. Studies in other disciplines suggest increased patient volume is related to improved guideline adherence and fewer complications. We hypothesized that antibiotic use among children with new onset ALL is inversely proportional to a hospital’s inpatient pediatric volume. Methods: A retrospective study of new onset ALL patients was performed with 2009-11 data from the Pediatric Health Information System and Premier Perspective Data Warehouse. Inpatient antibiotic exposure rates, reported as antibiotic days/1,000 hospital days for the first 30 days, were summed. Hospital volume was defined as the average annual number of 1–19-year-old inpatient stays. Association of volume and antibiotic use was evaluated by nonparametric trend test. Results: 3,434 patients were identified from 71 hospitals. Broad-spectrum antibiotic exposures were frequent, particularly cephalosporins. While total antibiotic rates did not differ, quinolone and carbapenem use increased with pediatric volume (Table). Conclusions: Children with ALL are frequently exposed to broad-spectrum antibiotics at diagnosis. Hospitals with increased pediatric volume prescribed more quinolones and carbapenems. This finding counters our hypothesis that more tailored antibiotic use was expected in higher-pediatric volume hospitals. Further analyses are needed to confirm these findings and to investigate the etiology of this association. Antibiotic days/1,000 hospital days by hospital volume (mean +/- SE). Hospital Pediatric Volume per Year Low (<6,000, n=24) Medium (6,000-8,000, n=24) High (>8,000, n=23) All 707+/-61 671+/-55 729+/-37 Gram Positive1 149+/-30 92+/-17 117+/-14 PCN2 102+/-28 63+/-35 127+/-37 Cephalosporin3 364+/-44 408+/-37 374+/-38 Aminoglycoside4 45+/-13 53+/-17 41+/-10 Quinolone5* 7.5+/-5 9.7+/-3 10+/-3.7 Carbapenem6** 37+/-15 45+/-12 59+/-28 P values reported are for trend. 1 Vancomycin, Linezolid. 2 Anti-Pseudomonal and b-Lactamase Combination Penicillins. 3 Cephalexin, Cefazolin, Cefoxitin, third and fourth generation. 4 Amikacin, Gentamicin, Tobramycin. 5* Ciprofloxacin, Levofloxacin; p=0.025. 6** Imipenem, Meropenem, p=0.048.
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: An ex vivo experiment in human serous ovarian carcinoma.
Authors: Stephanie Lheureux, Monique N'Diaye, Cecile Blanc-Fournier, Audrey Emmanuelle Dugue, Benedicte Clarisse, Soizic Dutoit, Florence Giffard, Edwige Abeilard, Melanie Briand, Alexandre Labiche, Jean-Michel Grellard, Hubert Crouet, Sandrine Martin, Florence Joly, Laurent Poulain
Journal: Journal of Clinical Oncology (2014)

5577 Background: Ovarian cancers are addicted to Bcl-xL and Mcl-1, anti-apoptotic members of the Bcl-2 family. Bcl-xL can be inhibited by the BH3-mimetic ABT-737. In vitro, ABT-737 can induce apoptosis of cancer cells, and its activity is potentiated by Mcl-1 inactivation. Methods: Here we assessed the sensitivity of human ovarian tumor nodes to ABT-737 when combined with carboplatin, which can indirectly inhibit Mcl-1. Fresh samples from 25 high-grade serous ovarian cancer (HGSOC) chemo-naïve patients who had undergone surgery were prospectively exposed ex vivo to ABT-737 alone or in combination with carboplatin. The treatment effect was studied on sliced tumor nodes by assessment of cleaved-caspase 3 immunostaining. We also studied the association between baseline Bcl-2 family protein expression (immunohistochemistry) and the response of nodes to treatment (NCT01440504). Results: ABT-737 induced massive apoptotic cell death as single agent but its efficacy was not improved by the addition of carboplatin. Bim was frequently expressed (20/25) and its absence or low expression was associated with the absence of response to ABT-737, p value = 0.019 by Fisher’s test and sensitivity = 93%, (95% confidence interval, 66-100). Moreover, we observed that in tumors in which Bim was expressed, a low expression of Mcl-1 or phospho-ERK1/2 improved the proportion of responses. Conclusions: This pilot study showed that ABT-737 has promise as monotherapy for HGSOC in a specific subgroup of tumors. Bim, Mcl-1 and phospho-ERK1/2 appeared to be relevant biomarkers that could be used for the selection of patients in the design of clinical trials using navitoclax (an orally available compound related to ABT-737). Clinical trial information: NCT01440504.
Abstract 17525: Single-Session versus Staged Procedures for Elective Multi-Vessel Percutaneous Coronary Intervention
Authors: Toshiaki Toyota, Takeshi Morimoto, Hiroki Shiomi, Kyohei Yamaji, Kenji Ando, Koh Ono, Satoshi Shizuta, Naritatsu Saito, Takao Kato, Shuichiro Kaji, Yutaka Furukawa, Yoshihisa Nakagawa, Kazushige Kadota, Minoru Horie, Takeshi Kimura
Journal: Circulation (2017)

Introduction: There are only a few studies comparing the single-session versus staged multi-vessel percutaneous coronary intervention (PCI) procedures in patients with stable coronary artery diseas...
Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry
Authors: Sudipto Mukherjee, Mehrdad Abedi, Harry P. Erba, Daniel A Pollyea, Gail J. Roboz, Michael A. Thompson, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, Christopher R. Cogle
Journal: Blood (2018)
Outcome of patients with multiple myeloma (MM) requiring intensive care unit: Single center experience.
Authors: Ankit Anand, Karthika raya Linga, Hussam Al-Sharif, Ali Al-Ameri
Journal: Journal of Clinical Oncology (2014)

e19570 Background: Therapeutic advances have positively impacted outcome in pts suffering from MM. Hospital mortality has decreased over past 15 years in MM pts admitted to intensive care unit (ICU). There is however limited data on long term outcome for MM pts who require ICU at any point during disease course. Aim: Study long term outcome of MM pts requiring ICU admission. Methods: A retrospective study on MM pts from 2000-2012 was conducted at Akron General Medical Center, Ohio, US. After IRB approval, 176 pts were identified from hospital database with established diagnosis of MM. Charts were searched for ICU admissions at any point during the disease course. Step down units were considered as ICU. Pts were followed for 200 weeks, at which point 36 (20%) pts were lost to follow up. 140 (80%) pts were studied and data analyzed. Kaplan Meier survival analysis was done for pts who were admitted to ICU compared to pts who did not require ICU. Logistic regression analysis was performed to determine if use of pressors, ventilator, dialysis and ICU length of stay (LOS) predicted survival at 200 weeks. Results: Of 140 pts, 46 (33%) pts were admitted to ICU. 35 (76%) pts were admitted less than one year from diagnosis. Most common reason for ICU admission was respiratory failure, in 18 (39%) pts. Mean survival for ICU pts was 94 weeks, compared to 235 weeks for non ICU pts. Median survival for ICU pts was 33 weeks as compared to 90 weeks for non ICU pts (P=.005). At 200 weeks, 40 (87%) of the pts admitted to the ICU had died. Results of logistic regression analysis found that likelihood of death in ICU pts increased 2.4 times for every one day increase in ICU LOS. (β=.867, χ2(1,46)=3.953, p=.047). Pressor use, ventilator support & dialysis were not significant predictors of mortality. Additionally, overall model was not significant predictor of mortality at 200 weeks in pts admitted to ICU. Conclusions: In our study, a large portion (1/3) of pts with MM required ICU admission. Mean & median survival in pts who required ICU was significantly decreased. Risk of mortality was found to increase based on the ICU LOS. Results of this research support performance of larger studies to determine other predictors of mortality in pts with MM requiring ICU during disease course.
The Need for a Consensus Next‐generation Sequencing Panel for Mature Lymphoid Malignancies
Authors: Pierre Sujobert, Yannick Le Bris, Laurence de Leval, Audrey Gros, Jean Philippe Merlio, Cedric Pastoret, Sarah Huet, Clémentine Sarkozy, Frédéric Davi, Mary Callanan, Catherine Thieblemont, David Sibon, Vahid Asnafi, Claude Preudhomme, Philippe Gaulard, Fabrice Jardin, Gilles Salles, Elizabeth Macintyre
Journal: HemaSphere (2019)

Supplemental Digital Content is available in the text.
Prognostic value of several inflammatory markers in pancreatic cancer patients.
Authors: Dai Inoue, Ikuhiro Yamada, Masato Ozaka, Masato Matsuyama, Kouichi Takano, Hiroshi Ishii
Journal: Journal of Clinical Oncology (2014)

e15213 Background: Recent studies showed that the prognosis of cancer patients was strongly associated with pre-treatment systemic inflammation. Although several inflammatory markers were proposed, the data is lacking about their validity for large Japanese cohort. Methods: This is a retrospective study to examine prognostic value of inflammatory markers, i.e., C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and modified Glasgow Prognostic Scale (mGPS). Selection criteria was as follows; patients who 1) admitted between January 2008 and December 2012, 2) had histologically confirmed exocrine pancreatic cancer, 3) had a diagnosis of invasive ductal cancer compatible by CT imaging, and 4) had been followed by death or for 90 days or more. The primary endpoint was overall survival, which was measured from the day of histological diagnosis. Results: There were 465 patients who met the selection criteria. Among the 465, 204 received pancreatectomy, 257 received systemic chemotherapy, and the remaining 4 received supportive care. In univariate analysis, body-tail tumor, advanced CT stage, high CRP level (≥1.0mg/dl), high NLR (≥2.0), and high CA19-9 level (≥1000U/ml) were significantly associated with poor survival. The ROC analysis revealed the optimal cut-off level of CRP and NLR was 0.13 and 1.7, respectively. Multivariate Cox regression analysis showed CRP (hazard ratio: 1.695, P<0.001), NLR (hazard ratio: 1.414, P=0.020), CA19-9 and CT Stage were identified as independent prognostic factors. Conclusions: Among the 4 inflammatory markers tested in this study, CRP and NLR produced the same positive results to previous reports, although PLR and mGPS did not show reproducibility in our cohort.
Comparative tolerability and efficacy of panitumumab (P) and cetuximab (C) in metastatic colorectal cancer (mCRC) treatment.
Authors: Natalya A Abramova, Oleg Ivanovich Kit, Liubov Yu Vladimirova
Journal: Journal of Clinical Oncology (2014)

e14641 Background: The addition anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAb) to chemotherapy (CT) results to improvement of survival in metastatic colorectal cancer (mCRC). However, MAb’s differences insufficiently studied. We performed this study to evaluate the comparative tolerability and efficacy of the combinations of panitumumab (P) and cetuximab (C) with standard chemotherapy (CT). Methods: Mutation analysis of KRAS (codons12,13) was done on samples at diagnosis. Elegibility criteria included measurable wild type (WT) KRAS mCRC, Eastern Cooperative Oncology Group (ECOG) score ≤2, adequate liver, kidney and bone marrow function, no brain metastases. P was administered 6mg/kg 1 day q2w. C was administered 400mg/m² 1day and 250mg/m² q1w. Combination with CT was allowed. Endpoints include response rate (RR),overall survival (OS), progression free survival (PFS) and anti-EGFR-specified toxicities. Results: Sixty patients (pts) (39 male and 21 female) were recruited. Thirty pts received C and 30 pts –P. Anti-epidermal growth factor receptor (EGFR) were combined with cytotoxic CT: 45.0%(27) in the first line FOLFOX-6 and 33.3% (20) in the second line FOLFIRI. Response rate (RR) in C group was 6 PR (20.0%) and 17 SD (56.7%), Med OS=16.3±5.1mo, Med PFS= 5.3±1.6mo. RR in P group was 7PR (23.3%) and 15SD (50.0%), Med OS=17.1±4.8mo, Med PFS=5.8±1.4mo. Anti-EGFR -specified toxicities in C group were: skin rash 2Gd–13.3%(4) and 3Gd 86.7%(26), rash appeared 1.5±0.8 week after C was started, xeroderma 2Gd-30.0%(9),skin itch 1/3Gd-53.3%(16), paronychia 2Gd-10.0%(3), blepharitis 2Gd-10.0%(3). Toxicities in P group were: skin rash 2Gd – 33.3%(10) and 3Gd 60.0%(18), rash appeared 4.4±1.2 week after P was started, xeroderma 2Gd-36.7%(11),skin itch 1/3Gd-56.7%(17), paronychia 2Gd-26.6%(8), blepharitis 2Gd-6.7%(2). Differences in skin rash 3Gd (p=0.013), paronychia 2Gd (p=0.021) and term of appearance of the rash (p=0.017) are statisticaly valid. Conclusions: These results consider equal efficiency both anti-EGFR agents in pts with mCRC, but identified differences in anti-EGFR-specified toxicity C and P. The data obtained will be taken into account when selecting the target combined with CT. epidermal growth factor receptor (EGFR)
Targeting oncogenic STAT3 and STAT5 signaling with on 146040, a small molecule inhibitor of PI3K α/δ and BCR-ABL.
Authors: Stephen Cosenza, Gayatri Panda, DRC Venkata Subbaiah, Balireddy Akula, Muralidhar Mallireddigari, Venkat Pallela, M V Ramana Reddy, E. Prekumar Reddy
Journal: Journal of Clinical Oncology (2014)

e13562 Background: The signal transducer and activator of transcription (STAT) family of proteins are important intracellular mediators. Two of these family members, STAT3 and STAT5, have been found to be dysregulated in human cancer and are thought to have important roles in tumorigenesis. STAT3 can be activated in tumors by growth factor regulators, such as PI3K. STAT5 signaling is also aberrant in human cancer, most notably in CML through direct activation by BCR-ABL. We recently identified a small molecule inhibitor that targets the PI3K α/δ isoforms (with IC50 ≈ 14 and 20 nM for α and δ isoforms, respectively) and BCR-ABL (IC50 ≈ 20 nM) and abrogates the oncogenic signaling of STAT3 and STAT5. Although inhibitors of STAT3 and STAT5 are being developed for various therapeutic applications (Nat Rev Drug Discov. 2013 Aug;12(8):611-29), ON 146040 represents the first dual PI3K and BCR-ABL inhibitor that targets the STAT3 and STAT5 pathways. Methods: Cellular assays were performed in leukemia, lymphoma, and myeloma cell lines. Proliferation was evaluated using the CellTiter-Blue Cell Viability Assay, and protein expression/phosphorylation was measured by immunoblotting. In vitro kinase assays were performed using recombinant proteins. Results: ON 146040 was highly potent in killing hematologic tumor cells with IC50 values in the 150 to 1,000 nM range. In biochemical testing, ON 146040 inhibited PI3K α/δ isoforms (IC50 ≈ 14 and 20 nM, respectively) without having a major effect on β/γ isoforms (IC50 ≈ 3 and 1 μM, respectively). ON 146040 was also found to inhibit Abl1 and several mutant versions of this kinase (IC50 < 150 nM), although the compound was not found to be active against the T315I mutant. Following treatment with ON 146040, STAT3 and STAT5 phosphorylation were down-regulated in leukemia and myeloma cells. Conclusions: We have identified a novel anti-cancer agent, ON 146040, which disrupts the oncogenic activity of both STAT3 and STAT5 by targeting upstream activators, including PI3K α and δ isoforms as well as wild type and mutant BCR-ABL. Future studies are planned to identify hematologic tumors that rely on these signals to survive.
Genetic variant in fragile histidine triad gene (<i>FHIT</i>) and mortality in prostate and breast cancers: Results from the Prostate, Lung, Colon, Ovarian Cancer Screening Trial (PLCO) and Women’s Health Initiative (WHI).
Authors: Yan Ding, Amanda Black, Ann W. Hsing, Gerald L. Andriole
Journal: Journal of Clinical Oncology (2014)

5076 Background: Prostate and breast cancers combined account for over 10% of all cancer deaths each year in the U.S. Previous studies detected familial concordance in prostate and breast cancer-specific mortality, suggesting shared genetic component associated with poor survival in the two cancers. We previously identified a genetic locus associated with prostate cancer in a 28.5 kb intronic region of FHIT, a triphosphatase that promotes apoptosis in response to DNA damage in epithelial cell.To evaluate its association with mortality, a prostate cancer cohort nested in the PLCO (n=1239) and a breast cancer cohort nested in the WHI (n = 682) were studied. Methods: We obtained data on genotypes, tumor characteristics, and outcomes from dbGaP and PLCO, and imputed genotypes for genetic variants within the 28.5 kb region. Multivariable-adjusted Cox proportional hazard regression was used to calculate hazard ratio (HR) of genotypes on mortality due to prostate cancer, breast cancer, or due to all causes, with 95% confidence intervals (CI). Other variables included in the models were age at diagnosis, PSA, Gleason score, stage, and primary treatment for prostate cancer and age at diagnosis for breast cancer. Results: We identified a common genetic variant in the FHIT locus associated with mortality due to prostate cancer (GG or AG vs. AA, HR = 2.96, 95% CI, 1.05 – 8.27, p = 0.04) or due to breast cancer (HR = 3.76, 95% CI, 1.4 – 10.2, p = 0.01). Furthermore, the variant was associated with all cause mortality in patients who had prostate (HR = 1.98, 95% CI, 1.3 – 3.1, p = 0.003) or breast (HR = 2.00, 95% CI, 1.00 – 1.05, p = 0.017) cancer. The association was stronger in patients who were diagnosed at younger ages or had family history in first degree relatives. We also detected interaction between the FHIT variant and treatments with radical prostatectomy or radiation therapy on prostate-cancer specific mortality (Pinteraction = 0.0045). Conclusions: The significant effect of the FHIT variant on mortality in both prostate and breast cancers suggests a role for the FHIT region on cancer outcomes, justifying further investigation.
Abstract 17232: Eliminate Thromboembolism: Improving Anticoagulation in Non-Valvular Atrial Fibrillation Patients' (ELITE) Registry - Insights From the Baseline Results
Authors: Abhinav Sharma, Adrian F Hernandez, Pearl Zakroysky, Melissa Hamilton, Emily C O'Brien
Journal: Circulation (2017)

Introduction: Prior studies of patients with non-valvular atrial fibrillation (NVAF) have reported suboptimal warfarin management and low levels of shared-decision making. However, few data are ava...
BCC 和 SCC 患者的需求和喜好
Authors: S. Egmond, M. Wakkee, M. Droger, M.T. Bastiaens, A. Rengen, K.P. Roos, T. Nijsten, M. Lugtenberg
Journal: British Journal of Dermatology (2019)

基底细胞癌 (BCC) 和鳞状细胞癌 (SCC) 是两种最常见的皮肤癌亚型。在 2013 年全世界有大约 550 万人至少发生这些癌症中的一种,且这一数字仍在上升。为了明确这些患者对于他们医疗保健的需求和喜好,作者们(来自荷兰 Erasmus MC 的皮肤科)邀请皮肤癌患者进行了小组访谈。共有 42 名 BCC 或 SCC 患者参与,他们被分为 6 个组来分享他们的想法和观点。这些焦点小组全部接受录音,并进行逐字转抄。接下来,将这些文件传入软件程序‘Atlas.ti’内。2 名作者为这些文本分配代码,以捕获其含义。之后将这些代码聚合成处理相同主题的代码组。最后,作者可以确定哪些主要主题对患者而言最为重要。BCC 和 SCC 患者对医疗保健的需求和喜好的相似性令人惊讶的高。两个患者组均表示,他们需要 (1) 收到所有的相关量身定制的信息(2) 一名能认真对待患者并能良好沟通的医生 (3) 等待期短且有直接结果的最佳治疗 (4) 接受来自同一医生的治疗 (5)治疗、(6) 随访和 (7) 结构式随访治疗期间,(8) 包括全身皮肤检查,对皮肤科医生的偏好。此外,BCC 患者表达了对于开放和透明以及参与他们医疗保健相关决策的需求。通过了解患者现在想要什么,可以将他们的视角添加到现行指南中,并将患者置于治疗的中心。